Skip to main content
Clinical Trials/NCT00134472
NCT00134472CompletedPhase 3

Therapeutic Strategy for Severe Head Trauma Patients With Mild Hypothermia and Estimation of Medical Expenses in Japan

Yamaguchi University Hospital43 sites in 1 country150 target enrollmentStarted: December 1, 2002Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
150
Locations
43
Primary Endpoint
Neurological outcome

Study Overview

Brief Summary

The purpose of this trial is to determine if mild hypothermia therapy, for severe head trauma patients, improves neurological outcome.

Detailed Description

Mild hypothermia therapy shows protective effects for damaged brains of animals and post cardiac arrest patients. However, Clifton et al. reported that mild hypothermia has no protective effect for severe head trauma but has a risk of complications. In this study, all the participants must be treated with continuous monitoring of cardiac output and jugular venous oxygen saturation to get optimal physiological conditions. Adequate anesthesia such as neuroleptanesthesia is essential to maintain organ function and tissue microcirculation. Participants are randomly assigned to two groups of mild hypothermia (32.0 - 34.0 degree Celsius) and anti-hyperthermia (35.5 - 37.0 C). The body temperature must be kept for at least 72 hours. Hypothermia must be induced within 6 hours after traumatic brain injury. Glasgow outcome score at 6 months after injury and the total medical expenses of the two groups will be evaluated.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
15 Years to 69 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Traumatic brain injury; Glasgow coma score 4-8 (motor 1-5).
  • •Hypothermia or anti-hyperthermia must be induced within 6 hours after injury.

Exclusion Criteria

  • •Systolic blood pressure < 90mmHg (after resuscitation)
  • •Thrombocytopenia (platelets [Plt] < 50,000/mm3)
  • •Pregnancy
  • •Preexisting medical conditions of severe hepatic dysfunction, heart failure or any other severe organ failure
  • •Deep drunkenness

Outcomes

Primary Outcomes

Neurological outcome

Time Frame: six months after the onset

Glasgow outcome score and neuropsychological performance at 6 months after injury.

Total medical expenses

Time Frame: whole duration of treatment

Total medical expenses would be compared.

Secondary Outcomes

  • Laboratory data(each day during the treatment)
  • Physiological data(each day during the treatment)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Tsuyoshi Maekawa

Honorary Professor

Yamaguchi University Hospital

Study Sites (43)

Loading locations...

Similar Trials